Janux Therapeutics Inc’s filing revealed that its President and CEO Campbell David Alan unloaded Company’s shares for reported $1.29 million on Nov 25 ’24. In the deal valued at $51.60 per share,25,000 shares were sold. As a result of this transaction, Campbell David Alan now holds 257,054 shares worth roughly $10.33 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Reardon Tighe bought 5,202 shares, generating $277,987 in total proceeds.
Before that, Lichter Jay bought 1,139 shares. Janux Therapeutics Inc shares valued at $60,723 were divested by the FORMER DIRECTOR at a price of $53.31 per share.
Leerink Partners initiated its Janux Therapeutics Inc [JANX] rating to an Outperform in a research note published on November 22, 2024; the price target was $79. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in late October with a ‘”a Buy”‘ rating. Stifel began covering JANX with “Buy” recommendation on September 06, 2024. Scotiabank started covering the stock on May 30, 2024. It rated JANX as “a Sector perform”.
Price Performance Review of JANX
On Monday, Janux Therapeutics Inc [NASDAQ:JANX] saw its stock fall -11.13% to $40.18. Over the last five days, the stock has lost -20.14%. Janux Therapeutics Inc shares have risen nearly 274.46% since the year began. Nevertheless, the stocks have risen 360.25% over the past one year. While a 52-week high of $65.60 was reached on 05/03/24, a 52-week low of $7.79 was recorded on 02/05/24. SMA at 50 days reached $49.68, while 200 days put it at $44.82.
Levels Of Support And Resistance For JANX Stock
The 24-hour chart illustrates a support level at 38.17, which if violated will result in even more drops to 36.15. On the upside, there is a resistance level at 44.05. A further resistance level may holdings at 47.91. The Relative Strength Index (RSI) on the 14-day chart is 27.23, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.92%. Stochastics %K at 1.93% indicates the stock is a buying.
How much short interest is there in Janux Therapeutics Inc?
A steep rise in short interest was recorded in Janux Therapeutics Inc stocks on 2024-11-15, dropping by -0.15 million shares to a total of 4.19 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 4.33 million shares. There was a decline of -3.5%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 21, 2024 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $62 price target.
